Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,489 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03379844 | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | completed | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05047146 |
| The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt |
| completed |
| — |
| 530 |
| Sadat City UniversityOTHER |
| 1 |
| Oct 25, 2022 |
| clinicaltrials |
| NCT04780802 | Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma | completed | N/A | 10 | Chinese University of Hong KongOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT01176604 | Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma | completed | N/A | 299 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT04420026 | Study of Automatic Image Fusion of a CT Volume With Ultrasound During Percutaneous Ablation Treatment of Hepatic Tumors(IAT) | completed | N/A | 44 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT00740753 | Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option(Y-90HDE) | completed | N/A | 339 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT02072356 | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Early Phase 1 | 290 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT02582918 | Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5 | completed | N/A | 2,871 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05545046 | Predictive Model for Pain After TACE | completed | — | 228 | Yantai Yuhuangding HospitalOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT05535998 | TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | completed | — | 743 | Yunfei YuanOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05307926 | Postoperative Adjuvant Therapy of HCC Based on PD-1 | completed | — | 573 | Chen XiaopingOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05178524 | Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma | completed | N/A | 180 | Tongji HospitalOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT05111795 | Holmium-166 Retrospective Collection of Real-World Data(RECORD) | completed | — | 146 | Terumo Europe N.V.INDUSTRY | 7 | Aug 30, 2022 | clinicaltrials |
| NCT04295330 | Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy | completed | N/A | 260 | West China HospitalOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05517239 | Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment(PEACH) | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT02115373 | c-Met Second-Line Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03232593 | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | completed | — | 1,758 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02141906 | A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin | completed | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05502458 | Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05489692 | HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | completed | — | 43 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT03163992 | Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | completed | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05464706 | Study on the Quality of Life (QoL) After Liver Surgery | completed | N/A | 60 | Humanitas Clinical and Research CenterOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01896778 | Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer | completed | N/A | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02072486 | Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | N/A | 30 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02412579 | Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation | completed | — | 40 | Baylor Research InstituteOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03982407 | 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma | completed | Early Phase 1 | 5 | Ajit H. Goenka, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02095678 | Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions | completed | N/A | 52 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02686372 | A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation | completed | Phase 1 | 13 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02929082 | Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer(FORCE) | completed | N/A | 97 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT00247728 | PI-88 in Hepatocellular Carcinoma After Hepatectomy | completed | Phase 2 | 172 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05406089 | Effects of Antiviral Therapy on Patients With HBV-related HCC | completed | — | 494 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Jun 21, 2022 | clinicaltrials |
| NCT02243384 | Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma | completed | N/A | 150 | ChenJianOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT03156582 | Impacts of the α-fetoprotein (AFP) Score in Real Life for Patient Selection for Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)(Impact AFP) | completed | — | 562 | University Hospital, GrenobleOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT04303286 | The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma | completed | — | 200 | Tongji HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04027556 | Low-contrast Dose Liver CT Using Lean Body Weight Low Monoenergetic Images and Deep Learning-based Reconstruction | completed | N/A | 90 | Seoul National University HospitalOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT05355662 | Prognosis Analysis of Elderly Donor Liver in Liver Transplantation | completed | — | 11,569 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT01929902 | Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery | completed | — | 20 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT00605150 | HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC | completed | — | 11 | Wake Forest University Health SciencesOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT01666145 | Advanced Image Guidance Utilized in Liver Surgery | completed | N/A | 14 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05068193 | A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers | completed | Phase 1 | 57 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02354898 | A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 60 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02358395 | A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 12 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04767750 | Role of LncRNA H19 in The Regulation of IGF-1R Expression | completed | — | 101 | Mansoura UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 1, 2022source: clinicaltrials